Payment overview · 2025
General Payments
$848.52
45 reported records · 11 companies
Healthcare provider profile · identity verified
Alan M Harben, M.D.,PHD
Allopathic & Osteopathic Physicians|Physical Medicine & Rehabilitation|Pain Medicine · ROSWELL, GA · NPI 1669652095
Verified facts
What the public records show
CMS Open Payments records show Alan M Harben, M.D.,PHD received $848.52 in general payments during 2025 across 45 reported records.
ABBVIE INC. accounted for 35.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Botox.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BOTOX as an associated drug or biological on 140321 records involving 30103 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Botox by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GENOTROPIN as an associated drug or biological on 864 records involving 515 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Genotropin by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Austedo by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $300.35 | 35.4% | 14 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $188.83 | 22.2% | 12 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $91.51 | 10.8% | 5 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $89.10 | 10.5% | 4 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $36.01 | 4.2% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $31.77 | 3.7% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $30.68 | 3.6% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $26.70 | 3.1% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $21.43 | 2.5% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.76 | 2.1% | 1 | 2025 |
| MicroTransponder, Inc. | Unresolved — no canonical attribution shown | $14.38 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $848.52 | 45 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $222.25 | 10 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $188.83 | 12 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $75.51 | 4 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $72.15 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $52.45 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $42.70 | 2 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $40.74 | 2 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $36.01 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $31.77 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $30.68 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $21.43 | 1 | 2025 |
Source payment records
|
|||||
| EDARBI Normalized: edarbi |
Drug | Azurity Pharmaceuticals, Inc. | $17.76 | 1 | 2025 |
Source payment records
|
|||||
| AJOVY Normalized: ajovy |
Biological | Teva Pharmaceuticals USA, Inc. | $16.95 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.82 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| BOTOX botox |
2025 | Botox | 2024 | 21 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | BOTOX open payments reported associated product |
CMS Open Payments — General Payments 140321 supporting records · 30103 recipient NPIs · example record 1201352642 |
Botox · 2024 Exact normalized brand match · 1 Part D row |
21 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
39 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | GENOTROPIN open payments reported associated product |
CMS Open Payments — General Payments 864 supporting records · 515 recipient NPIs · example record 1228794127 |
Genotropin · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 202 | 43 |
| Trazodone Hcl | Trazodone Hcl | 171 | 27 |
| Amantadine | Amantadine Hcl | 150 | 42 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 150 | 22 |
| Atorvastatin Calcium | Atorvastatin Calcium | 128 | 29 |
| Sertraline Hcl | Sertraline Hcl | 125 | 16 |
| Clonazepam | Clonazepam | 121 | 16 |
| Oxycodone Hcl | Oxycodone Hcl | 105 | 22 |
| Aripiprazole | Aripiprazole | 100 | 16 |
| Baclofen | Baclofen | 96 | 17 |
| Lamotrigine | Lamotrigine | 86 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 82 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 82 | 19 |
| Levetiracetam | Levetiracetam | 75 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 68 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 65 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 62 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 60 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 59 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 51 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 49 | 17 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 47 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 46 | 20 |
| Morphine Sulfate Er | Morphine Sulfate | 45 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 44 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 43 | suppressed |
| Metformin Hcl | Metformin Hcl | 43 | suppressed |
| Fentanyl | Fentanyl | 42 | suppressed |
| Pregabalin | Pregabalin | 42 | 11 |
| Carvedilol | Carvedilol | 39 | 13 |
| Eliquis | Apixaban | 39 | 16 |
| Methocarbamol | Methocarbamol | 38 | 13 |
| Donepezil Hcl | Donepezil Hcl | 36 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 36 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 36 | 14 |
| Oxycontin | Oxycodone Hcl | 36 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 34 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 33 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 30 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 30 | suppressed |
| Tradjenta | Linagliptin | 30 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 29 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 29 | 11 |
| Lorazepam | Lorazepam | 28 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 27 | suppressed |
| Losartan Potassium | Losartan Potassium | 26 | suppressed |
| Lisinopril | Lisinopril | 25 | suppressed |
| Nabumetone | Nabumetone | 24 | suppressed |
| Memantine Hcl | Memantine Hcl | 23 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 22 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 22 | suppressed |
| Omeprazole | Omeprazole | 22 | suppressed |
| Botox | Onabotulinumtoxina | 21 | 11 |
| Xtampza Er | Oxycodone Myristate | 21 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | 15 |
| Finasteride | Finasteride | 19 | suppressed |
| Simvastatin | Simvastatin | 19 | suppressed |
| Carisoprodol | Carisoprodol | 18 | suppressed |
| Meloxicam | Meloxicam | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Temazepam | Temazepam | 16 | suppressed |
| Allopurinol | Allopurinol | 15 | suppressed |
| Famotidine | Famotidine | 15 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 15 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 15 | 11 |
| Potassium Chloride | Potassium Chloride | 15 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 15 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 14 | suppressed |
| Jardiance | Empagliflozin | 14 | suppressed |
| Nucynta | Tapentadol Hcl | 14 | suppressed |
| Austedo | Deutetrabenazine | 13 | suppressed |
| Celecoxib | Celecoxib | 13 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 13 | suppressed |
| Lactulose | Lactulose | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 13 | suppressed |
| Genotropin | Somatropin | 12 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 12 | suppressed |
| Seroquel | Quetiapine Fumarate | 12 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 12 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 12 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Ozempic | Semaglutide | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $848.52 · 45 records | ABBVIE INC. | AJOVY, AUSTEDO XR, Auvelity, BOTOX, CAPLYTA, EDARBI, INGREZZA, NURTEC ODT, QULIPTA, QUTENZA, REXULTI, UBRELVY, VYEPTI, ZAVZPRET | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Botox play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error